Relationship between BRAF V600E mutation and recurrence of differentiated thyroid cancer — a systematic review
, 2, 2
Abstract
Introduction. The BRAF V600E mutation is implicated in the tumorigenesis of differentiated thyroid cancer, and its role in cancer recurrence remains debated. This systematic review aims to assess the relationship between BRAF mutations and the recurrence of DTC and its impact on lymph node metastasis and mortality.
Methods. Following PRISMA 2020 guidelines, a comprehensive search was performed across PubMed and ScienceDirect databases covering studies published up to September 2024. Eligible studies reported on the association between BRAF V600E mutation and recurrence in DTC. Data on patient characteristics, recurrence rates, metastasis, and mortality were extracted for synthesis.
Results. A total of seven studies with 4660 patients were included. Most of the patients had papillary thyroid carcinoma, and the mean age ranged from 40 to 54 years. Three studies found no significant association between BRAF V600E mutation and DTC recurrence, while two studies reported a significant association. Lymph node metastasis was associated with BRAF mutation in three studies, without contradictory findings. Regarding mortality, two studies found no significant association, whereas one study reported an increased mortality risk with BRAF mutation.
Conclusions. The relationship between BRAF V600E mutation and recurrence in DTC is inconclusive, with mixed findings across the studies. BRAF V600E mutation is more consistently linked to lymph node metastasis, though its role in predicting recurrence and mortality remains uncertain. Further research with standardized methodologies is required to better understand the clinical implications of BRAF V600E mutations in DTC.
Keywords: BRAF mutationdifferentiated thyroid cancerrecurrencemetastasismortality.
References
- Cappellacci F, Canu GL, Piras S, et al. Technological Innovations in Thyroid Cancer Surgery. Oncologie. 2022; 24(1): 35–50.
- Toraih EA, Hussein MH, Jishu JA, et al. Initial versus Staged Thyroidectomy for Differentiated Thyroid Cancer: A Retrospective Multi-Dimensional Cohort Analysis of Effectiveness and Safety. Cancers (Basel). 2024; 16(12).
- Zhang H, Li S, Li W. Development of a Prognostic Signature Based on Hypoxia-related Genes for Thyroid Cancer. Research Square. 2021.
- Wahba H, El-Hadaad H, Anter A, et al. Impact of Thyroglobulin on Survival and Prognosis of Differentiated Thyroid Cancer. J Cancer Ther. 2018; 09(09): 706–713.
- Patrone R, Velotti N, Masone S, et al. Management of Low-Risk Thyroid Cancers: Is Active Surveillance a Valid Option? A Systematic Review of the Literature. J Clin Med. 2021; 10(16).
- Liu R, Bishop J, Zhu G, et al. Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality. JAMA Oncol. 2017; 3(2): 202–208.
- Amin SN, Shinn JR, Naguib MM, et al. Risk Factors and Outcomes of Postoperative Recurrent Well-Differentiated Thyroid Cancer: A Single Institution's 15-Year Experience. Otolaryngol Head Neck Surg. 2020; 162(4): 469–475.
- Anwar SL, Cahyono R, Suwardjo S, et al. Extrathyroidal extension and cervical node infiltration are associated with recurrences and shorter recurrence-free survival in differentiated thyroid cancer: a cohort study. Thyroid Res. 2022; 15(1): 13.
- Lo TE, Canto AUy, Maningat PD. Risk Factors for Recurrence in Filipinos with Well-Differentiated Thyroid Cancer. Endocrinol Metab (Seoul). 2015; 30(4): 543–550.
- Harahap WA, Tofrizal T, Oktahermoniza O. Relationship between the Expression of BRAF V600E and Ki-67 with the Recurrence of Well-Differentiated Thyroid Cancer. Asian Pac J Cancer Prev. 2022; 23(11): 3617–3622.
- Tsai CY, Lin SF, Chen ST, et al. Therapeutic Outcomes of Recurrent Well-Differentiated Thyroid Carcinomas. Int Surg. 2021; 104(7-8): 304–313.
- Kim TH, Park YJ, Lim JAh, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012; 118(7): 1764–1773.
- Jafri S, Yaqub A. Redifferentiation of BRAF V600E-Mutated Radioiodine Refractory Metastatic Papillary Thyroid Cancer After Treatment With Dabrafenib and Trametinib. Cureus. 2021; 13(8): e17488.
- Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013; 309(14): 1493–1501.
- Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018; 36(1): 7–13.
- Liu R, Xing MT. Promoter Mutations in Thyroid Cancer. Endocrine Related Cancer. 2016.
- Barreno LR, Mello JB, Barros-Filho MC, et al. Characterization of BRAF mutation in patients older than 45 years with well-differentiated thyroid carcinoma. Braz J Otorhinolaryngol. 2022; 88(4): 523–528.
- Huang M, Yan C, Xiao J, et al. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Diagn Pathol. 2019; 14(1): 74.
- Bui Dang Minh T, Nghiem Duc T, Phan Nguyen Thanh V, et al. Relationships of BRAF V600E Gene Mutation With Some Immunohistochemical Markers and Recurrence Rate in Patients With Thyroid Carcinoma. Clin Med Insights Oncol. 2023; 17: 11795549231203503.
- Yan C, Huang M, Li X, et al. Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma. Endocr Connect. 2019; 8(7): 988–996.
- Krishnamurthy A, Ramshankar V, Murherkar K, et al. Role and relevance of BRAF mutations in risk stratifying patients of papillary thyroid cancers along with a review of literature. Indian J Cancer. 2017; 54(1): 372–378.
- Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014; 159(3): 676–690.
- Mady LJ, Grimes MC, Khan NI, et al. Molecular Profile of Locally Aggressive Well Differentiated Thyroid Cancers. Sci Rep. 2020; 10(1): 8031.
- Li R, Hao J, Zhu Z, et al. Correlation between US-FNAC with BRAF V600E Mutation Analysis and Central Neck Lymph Node Metastasis in cN0 Papillary Thyroid Cancer. Biomed Res Int. 2021; 2021: 9937742.
- Liu J, Liu R, Shen X, et al. The Genetic Duet of V600E and Promoter Mutations Robustly Predicts Loss of Radioiodine Avidity in Recurrent Papillary Thyroid Cancer. J Nucl Med. 2020; 61(2): 177–182.
- Sahin S, Daglar G, Menekse E, et al. The Effect of BRAF Mutation on Lymph Node Involvement in Papillary Thyroid Cancer. Turk J Surg. 2020; 36(3): 249–255.
- Wang X, Xu X, Peng C, et al. BRAF-induced KRT19 expression in thyroid cancer promotes lymph node metastasis via EMT. Oncol Lett. 2019; 18(1): 927–935.
- Fakhruddin N, Jabbour M, Novy M, et al. BRAF and NRAS Mutations in Papillary Thyroid Carcinoma and Concordance in BRAF Mutations Between Primary and Corresponding Lymph Node Metastases. Sci Rep. 2017; 7(1): 4666.
- Lai Y, Gu Y, Yu M, et al. Younger Than 55 Years Old and V600E Mutation are Risk Factors for Lymph Node Metastasis in Papillary Thyroid Carcinomas ≤1.0 cm but Not in >1.0 cm. Int J Gen Med. 2023; 16: 1403–1414.
- Huang K, Gao N, Bian D, et al. Associations of BRAF V600E, clinical pathology and imaging factors with the recurrence rate of papillary thyroid microcarcinoma. Exp Ther Med. 2020; 20(6): 243.